Printer Friendly

Cell Genesys obtains United States patent.

Cell Genesys, Inc. (Foster City, CA) and Whitehead Institute for Biomedical Research (Cambridge, MA) have patented retroviral vectors which include an insertion site for genes of interest and are capable of expressing high levels of the protein derived from the genes of interest in a wide variety of transfected cell types. Also disclosed are retroviral vectors lacking a selectable marker, thus rendering them suitable for human gene therapy in the treatment of a variety of disease states without the co-expression of a marker product, such as an antibiotic. These retroviral vectors are especially suited for use in certain packaging cell lines. (US 6,544,771)
COPYRIGHT 2003 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Whitehead Institute for Biomedical Research US patent
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:1USA
Date:Mar 1, 2003
Words:105
Previous Article:Oklahoma Medical Research Foundation obtains United States patent.
Next Article:Kao Corporation obtains United States patent.
Topics:


Related Articles
Thm Biomedical receives patent for a method and device for the reconstruction of articular cartilage.
Cell Genesys exclusively licenses technology for liver-directed Aav gene therapy from University of Washington.
ID Biomedical files patent infringement suit against third wave technologies.
Novavax co-invented hepatitis E vaccine technology licensed to SmithKline Beecham.
Cell Genesys obtains results from preclinical hemophilia gene therapy studies.
ID Biomedical announces collaboration with US Army on nasal vaccine.
Cell Genesys announces sale of Lentiviral gene delivery technology for $12 million.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters